Kim Hyong sold $270K of ALHC

Kim Hyong (Chief Medical Officer) sold 32,479 shares of Alignment Healthcare, Inc. (ALHC) at $8.30 ($0.27M total) on 2026-10-06.

Original reporting
SEC EDGAR · Kim Hyong
Published Oct 7, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Bearish
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which may influence short-term trading decisions.

02

Market read

A new Form 4 filing reveals a CMO's share sale, offering modest trading relevance for ALHC.

03

What to watch

Potential upcoming clinical data releases that may offset the sell pressure.

Relevance 4/10Novelty 5/10Timing: after-hours

Background

SEC Form 4 filing discloses an insider transaction by Alignment Healthcare's Chief Medical Officer.

Company-level read

Ticker impact

$ALHCBearishMedium confidence
Context

Chief Medical Officer Kim Hyong sold 32,479 shares of Alignment Healthcare for $269,576.

Expected impact

likely modest pressure as market prices in the insider sell

Evidence & confidence

A CMO selling a sizable block suggests limited confidence; the amount is small but may trigger short-term sell interest.

Market effects

Minimal impact on the broader healthcare sector.

Slight, localized effect on US biotech stocks.

Negligible on a global scale.

Counterpoint

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Kim Hyong

    Chief Medical Officer of Alignment Healthcare who sold shares.

  • Alignment Healthcare, Inc.

    US-listed biotech company (ticker ALHC) subject of the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.